Product image of Lipegis (Ezetimibe) supplied by GNH India

Lipegis

Active Ingredient:
Ezetimibe
Origin:
EU

Lipegis (Ezetimibe)

Ezetimibe, the active ingredient in Lipegis, is a cholesterol absorption inhibitor presented as a tablet for oral use. It lowers low‑density lipoprotein cholesterol in adults with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or mixed hyperlipidemia.

GNH India supplies Lipegis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed globally.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lipegis (ezetimibe) is used to manage disorders of lipid metabolism, primarily by reducing elevated cholesterol levels.

  • Hypercholesterolemia: lowers LDL‑C and total cholesterol in patients with primary high cholesterol.
  • Heterozygous familial hypercholesterolemia: provides additional LDL‑C reduction when combined with statins.
  • Hyperlipidemia: improves overall lipid profile, decreasing triglycerides and non‑HDL cholesterol.

How It Works

  • Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter on the brush border of intestinal enterocytes, preventing the uptake of dietary and biliary cholesterol. By inhibiting this pathway, the drug reduces the amount of cholesterol delivered to the liver, prompting up‑regulation of hepatic LDL receptors and resulting in decreased circulating LDL‑C levels.

Side Effects

Ezetimibe may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

  • Abdominal pain: mild discomfort in the stomach area.
  • Diarrhea: loose stools occurring intermittently.
  • Fatigue: feeling unusually tired.
  • Headache: mild to moderate head pain.
  • Nausea: sensation of needing to vomit.
  • Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects

  • Severe allergic reactions: including angioedema or anaphylaxis.
  • Hepatitis: inflammation of the liver with jaundice.
  • Rhabdomyolysis: muscle breakdown, especially when combined with statins.
  • Pancreatitis: inflammation of the pancreas.
  • Cholestatic jaundice: impaired bile flow leading to yellowing of skin and eyes.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Pregnancy: Category B; use only if the potential benefit justifies the potential risk to the fetus.
  • Breastfeeding: limited data; weigh maternal benefit against possible infant exposure.
  • Liver disease: monitor hepatic function tests regularly.
  • Concomitant statin therapy: assess risk of myopathy and adjust monitoring.
  • Renal impairment: no dose adjustment required, but monitor overall lipid profile.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Ezetimibe can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Cyclosporine: may increase ezetimibe plasma concentrations.
  • Fibrates combined with statins: heightened risk of myopathy.
  • Antacids containing aluminum or magnesium: can reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely)

  • Statins: additive LDL‑C lowering; monitor liver enzymes and muscle symptoms.
  • Warfarin: possible alteration of INR; check coagulation status regularly.
  • Bile acid sequestrants: may diminish ezetimibe efficacy; separate dosing by at least 2 hours.

Frequently Asked Questions

Lipegis contains ezetimibe and is prescribed to lower elevated low‑density lipoprotein cholesterol in patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or other forms of hyperlipidemia, often as part of a broader lipid‑lowering regimen.

Ezetimibe blocks the NPC1L1 transporter on intestinal cells, preventing the absorption of dietary and biliary cholesterol. This reduction in intestinal cholesterol delivery to the liver leads to increased hepatic LDL‑receptor activity and lower circulating LDL‑C levels.

The prescribed dose of Lipegis is determined by the treating physician based on the patient’s clinical condition, lipid profile, and any concomitant therapies. Dosage adjustments are made according to individual therapeutic response and safety considerations.

Lipegis is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit outweighs any possible risk. Limited data are available for breastfeeding; clinicians should consider the benefit‑risk balance before prescribing.

To order Lipegis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to ezetimibe is statin therapy, which inhibits hepatic cholesterol synthesis. Ezetimibe works by reducing intestinal cholesterol absorption, offering an additive effect when combined with statins. Unlike statins, ezetimibe does not significantly affect muscle tissue, making it useful for patients who cannot tolerate high‑dose statins.

Lipegis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lipegis is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe allergic reactions such as angioedema or anaphylaxis, hepatitis or other significant liver injury, and rare cases of rhabdomyolysis, especially when used together with high‑dose statins. Patients should report any unexplained muscle pain, jaundice, or signs of an allergic response immediately.

Lipegis is contraindicated in patients with known hypersensitivity to ezetimibe or any of its excipients. Caution is advised for individuals with active liver disease, severe renal impairment, or those taking medications that have major interactions, such as cyclosporine, without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT